Home » Posts tagged with » Drug discovery
AbbVie, Scripps Research to collaborate on developing new therapeutics

AbbVie, Scripps Research to collaborate on developing new therapeutics

US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for a variety of diseases, including in the therapeutic areas of oncology, immunology, fibrosis, and neurology. Peter Schultz – CEO of Scripps Research and Calibr, its drug discovery unit, said: “Based […]

GE Healthcare, ASLS form R&D partnership to advance 3D biofabrication

GE Healthcare Life Sciences has joined forces with Advanced Solutions Life Sciences (ASLS) for an R&D and distribution partnership with a goal to create new opportunities for regenerative tissue manufacturing by advancing the field of 3D biofabrication. The companies said that the integration of IN Cell Analyzer and BioAssemblyBot systems technologies will embed cellular-level evaluations […]

Continue reading …
AstraZeneca taps into Gatehouse Bio’s sRNAlytics AI platform for drug discovery

US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using sRNAlytics, the former’s artificial intelligence (AI)-driven platform. According to Gatehouse Bio, the sRNAlytics platform is capable of identifying new small RNA (sRNA) signatures and can illuminate molecular pathways correlated to […]

Continue reading …
Chinese biopharma company Akeso raises $150m for antibody drug discovery

Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a Series D funding round. The investment in the clinical stage company was led by Loyal Valley Capital (LVC) and Sino Biopharmaceutical. The co-investors in the Series D round are healthcare […]

Continue reading …
Yuhan Pharmaceuticals to use Cyclica’s AI-driven drug discovery platform

Yuhan Pharmaceuticals has entered into a collaboration with Canadian biotechnology company Cyclica to use the latter’s artificial intelligence (AI) driven integrated drug discovery platform in two separate research and development (R&D) programs in oncology. The South Korean healthcare company said that it is looking to adopt innovative technologies to boost its drug development efforts. In […]

Continue reading …
Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies

Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B virus (HBV) infection using its GalXC RNAi platform technology. The collaboration between the Dicerna Pharmaceuticals and the Swiss drugmaker will focus on the global development and commercialization of the former’s […]

Continue reading …
Pepticom secures investment for AI-driven peptide drug discovery

Israel-based Pepticom, which is engaged in using artificial intelligence (AI) for peptide drug discovery, has raised $5 million in a Series A funding round from the Chartered Group. Pepticom is a spin-out of Yissum, the technology transfer company of The Hebrew University of Jerusalem. The company’s artificial intelligence technology is said to optimize and significantly speed […]

Continue reading …
The Pritzker Organization invests in AI-driven Systems Oncology

Systems Oncology, which uses big data and AI to discover scientific insights into cancer biology, has secured an undisclosed investment from the Pritzker Family Business Interests advised by The Pritzker Organization (TPO) during the first closing of its Series B round. The new capital will be used for investing in discovery research and pre-clinical development […]

Continue reading …
Aptorum to develop drugs for treatment of obesity and neuroblastoma

Aptorum Group said that it will undertake the development of CLS-1 microbiome drug candidate and certain repurposed drug candidates for the treatment of obesity and neuroblastoma, respectively. Based in Hong Kong, Aptorum Group is a pharma company focused on the development of new drugs to treat unmet medical needs. The company said that its wholly-owned subsidiary […]

Continue reading …
BioMed, University of California open cancer research center in San Diego

The University of California San Diego (UC San Diego) and BioMed Realty have opened the Center for Novel Therapeutics (CNT) – a new cancer research center at the former’s Science Research Park in San Diego, California. The cancer research center in San Diego, which spans 137,500sft, has been developed with an investment of $92 million […]

Continue reading …
Page 1 of 212